US-based biopharmaceutical company Ligand has reported positive data from two Phase I trials reports of LGD-6972 to treat type 2 diabetes.

LGD-6972 is Ligand’s glucagon receptor antagonist, which activates a non-insulin mechanism to lower plasma glucose in type 2 diabetic patients.

The Phase Ia and Phase Ib trials were designed as single and multiple-dose, randomised, double-blind and placebo-controlled studies to determine the safety, tolerability and pharmacokinetics profile of LGD-6972 when administered to healthy subjects and patients with type 2 diabetes mellitus.

LGD-6972 was administered in single or multiple oral doses.

"LGD-6972 is Ligand’s glucagon receptor antagonist, which activates a non-insulin mechanism to lower plasma glucose in type 2 diabetic patients."

Results indicated the efficacy of the glucagon receptor antagonist in lowering fasting plasma glucose within both the healthy subjects and type 2 diabetes patients, recording an increase in insulin and a decrease in glucagon responding to an oral glucose load.

The study data also suggested the safety and tolerability of LGD-6972, recording no dose-dependent changes in hematology, clinical chemistry or urinalysis panels, electrocardiography or vital signs and no hypoglycemic event.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Ligand CEO John Higgins said: “These clinical results are encouraging as they demonstrate a favourable safety profile for LGD-6972 and show a robust glycemic response in both healthy subjects and subjects with diabetes."

The company is planning to start a Phase II trial to demonstrate additional safety and efficacy data of LGD-6972.

The trial will be designed as a randomised, double-blind, multicentre study and include 148 patients whose blood glucose levels are inadequately controlled with metformin.